Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• p53 mutations in cervical carcinogenesis--low frequency and lack of correlation with human papillomavirus status.

  PMID 8142262 · PMC1968818 · British journal of cancer · 1994 · 7 claims · 6 setups

  Full-text index only

  Somatic mutation in the p53 gene hotspot regions occurs infrequently in cervical carcinomas

  cervical tumour paired hpv-positive immunocytochemistry pcr sequencing

• Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction.

  PMID 12877750 · PMC183853 · BMC biotechnology · 2003 · 6 claims · 5 setups

  Full-text index only

  Polony technology can detect intragenic mutations in well-defined hotspots of p53 (codons 175, 245, 248, 249, 273, 282) and K-ras2 (codons 12, 13, 61)

  panc-1 aspc-1 capan-1 immobilized polony-based

• K-RAS and P53 mutations in association with COX-2 and hTERT expression and clinico-pathological status of NSCLC patients.

  PMID 18957720 · PMC3827803 · Disease markers · 2008 · 8 claims · 6 setups

  Full-text index only

  P53 mutations were identified in 34.4% of NSCLC tumours, most frequently in SCC (55.6%)

  nsclc dhplc quantitative clinical

• Intricate targeting of immunoglobulin somatic hypermutation maximizes the efficiency of affinity maturation.

  PMID 15867095 · PMC2213188 · The Journal of experimental medicine · 2005 · 7 claims · 6 setups

  Full-text index only

  IgVH genes have evolved precise placement of coding-strand Cs so that AID-induced C-to-T mutations are predominantly silent, especially in the CDRs.

  igvh germline non-igv immunogenetics flow cdna bioinformatic

• Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

  PMID 19010816 · PMC6953412 · Molecular cancer research : MCR · 2008 · 8 claims · 8 setups

  Full-text index only

  Activating RAS-MAPK pathway mutations are present in >70% of serous LMP tumors versus ~12.5% of serous ovarian carcinomas

  serous same lmp braf-mutant gene hotspot erbb2

• High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.

  PMID 17925008 · PMC2246289 · Genome biology · 2007 · 7 claims · 8 setups

  Full-text index only

  A novel subtype of high-grade ER-negative breast cancer exists, characterized by a low genomic instability index (GII)

  breast computational array-cgh gene bac